31 related articles for article (PubMed ID: 36722703)
21. Hypoglycaemia when adding sulphonylurea to metformin: a systematic review and network meta-analysis.
Andersen SE; Christensen M
Br J Clin Pharmacol; 2016 Nov; 82(5):1291-1302. PubMed ID: 27426428
[TBL] [Abstract][Full Text] [Related]
22. Glucose-lowering agents and risk of ventricular arrhythmias and sudden cardiac death: A comprehensive review ranging from sulphonylureas to SGLT2 inhibitors.
Scheen AJ
Diabetes Metab; 2022 Nov; 48(6):101405. PubMed ID: 36334794
[TBL] [Abstract][Full Text] [Related]
23. Sulphonylureas versus metformin and the risk of ventricular arrhythmias among people with type 2 diabetes: A population-based cohort study.
Islam N; Reynier P; Douros A; Yu OHY; Filion KB
Diabetes Obes Metab; 2023 Jun; 25(6):1523-1533. PubMed ID: 36722703
[TBL] [Abstract][Full Text] [Related]
24. Repaglinide : a pharmacoeconomic review of its use in type 2 diabetes mellitus.
Plosker GL; Figgitt DP
Pharmacoeconomics; 2004; 22(6):389-411. PubMed ID: 15099124
[TBL] [Abstract][Full Text] [Related]
25. Sulphonylurea monotherapy for patients with type 2 diabetes mellitus.
Hemmingsen B; Schroll JB; Lund SS; Wetterslev J; Gluud C; Vaag A; Sonne DP; Lundstrøm LH; Almdal T
Cochrane Database Syst Rev; 2013 Apr; (4):CD009008. PubMed ID: 23633364
[TBL] [Abstract][Full Text] [Related]
26. Insulin secretagogues for prevention or delay of type 2 diabetes mellitus and its associated complications in persons at increased risk for the development of type 2 diabetes mellitus.
Hemmingsen B; Sonne DP; Metzendorf MI; Richter B
Cochrane Database Syst Rev; 2016 Oct; 10(10):CD012151. PubMed ID: 27749986
[TBL] [Abstract][Full Text] [Related]
27. Oral antidiabetic agents: current role in type 2 diabetes mellitus.
Krentz AJ; Bailey CJ
Drugs; 2005; 65(3):385-411. PubMed ID: 15669880
[TBL] [Abstract][Full Text] [Related]
28. Cost effectiveness of combination therapy with pioglitazone for type 2 diabetes mellitus from a german statutory healthcare perspective.
Neeser K; Lübben G; Siebert U; Schramm W
Pharmacoeconomics; 2004; 22(5):321-41. PubMed ID: 15061682
[TBL] [Abstract][Full Text] [Related]
29.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
30.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
31.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Previous] [New Search]